Lincoln Pharmaceuticals Limited (LINCOLN.NS)
INR 572.8
(0.93%)
INR 572.8
(0.93%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.88 Billion INR | -29.83% |
| 2022 | 2.68 Billion INR | 8.25% |
| 2021 | 2.48 Billion INR | 15.08% |
| 2020 | 2.15 Billion INR | 11.79% |
| 2019 | 1.93 Billion INR | 7.01% |
| 2018 | 1.8 Billion INR | 11.8% |
| 2017 | 1.61 Billion INR | 30.73% |
| 2016 | 1.23 Billion INR | 18.46% |
| 2015 | 1.04 Billion INR | 38.79% |
| 2014 | 750.92 Million INR | 15.64% |
| 2013 | 649.38 Million INR | 7.31% |
| 2012 | 605.17 Million INR | 3.92% |
| 2011 | 582.32 Million INR | 5.99% |
| 2010 | 549.4 Million INR | 13.61% |
| 2009 | 483.59 Million INR | 400.71% |
| 2008 | 96.58 Million INR | 3.09% |
| 2007 | 93.68 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 447.99 Million INR | 8.8% |
| 2023 Q4 | 411.77 Million INR | -17.82% |
| 2023 FY | 1.88 Billion INR | -29.83% |
| 2023 Q1 | 717.75 Million INR | 12.22% |
| 2023 Q2 | 821.6 Million INR | 14.47% |
| 2023 Q3 | 501.08 Million INR | -39.01% |
| 2022 Q2 | 730.2 Million INR | 17.62% |
| 2022 Q3 | 698.46 Million INR | -4.35% |
| 2022 Q4 | 639.59 Million INR | -8.43% |
| 2022 Q1 | 620.84 Million INR | 19.36% |
| 2022 FY | 2.68 Billion INR | 8.25% |
| 2021 Q4 | 520.15 Million INR | -18.81% |
| 2021 FY | 2.48 Billion INR | 15.08% |
| 2021 Q1 | 648.37 Million INR | 47.48% |
| 2021 Q2 | 674.92 Million INR | 4.09% |
| 2021 Q3 | 640.64 Million INR | -5.08% |
| 2020 Q3 | 531.93 Million INR | -19.29% |
| 2020 Q2 | 659.1 Million INR | 24.84% |
| 2020 Q1 | 527.97 Million INR | 60.62% |
| 2020 Q4 | 439.64 Million INR | -17.35% |
| 2020 FY | 2.15 Billion INR | 11.79% |
| 2019 Q3 | 496.05 Million INR | -13.19% |
| 2019 Q4 | 328.7 Million INR | -33.74% |
| 2019 FY | 1.93 Billion INR | 7.01% |
| 2019 Q1 | 534.72 Million INR | 92.2% |
| 2019 Q2 | 571.44 Million INR | 6.87% |
| 2018 Q1 | 551.3 Million INR | 30.29% |
| 2018 Q4 | 278.21 Million INR | -41.77% |
| 2018 Q2 | 497.13 Million INR | -9.82% |
| 2018 Q3 | 477.75 Million INR | -3.9% |
| 2018 FY | 1.8 Billion INR | 11.8% |
| 2017 Q3 | 443.03 Million INR | 0.48% |
| 2017 FY | 1.61 Billion INR | 30.73% |
| 2017 Q4 | 423.14 Million INR | -4.49% |
| 2017 Q2 | 440.91 Million INR | 32.34% |
| 2017 Q1 | 333.17 Million INR | 29.1% |
| 2016 FY | 1.23 Billion INR | 18.46% |
| 2016 Q3 | 359.81 Million INR | -14.6% |
| 2016 Q2 | 421.32 Million INR | 9.81% |
| 2016 Q1 | 383.66 Million INR | 45.6% |
| 2016 Q4 | 258.08 Million INR | -28.27% |
| 2015 Q3 | 289.14 Million INR | -0.24% |
| 2015 Q1 | 271.97 Million INR | 147.27% |
| 2015 FY | 1.04 Billion INR | 38.79% |
| 2015 Q2 | 289.84 Million INR | 6.57% |
| 2015 Q4 | 263.5 Million INR | -8.87% |
| 2014 Q2 | 250.53 Million INR | 30.67% |
| 2014 Q4 | 109.99 Million INR | -44.63% |
| 2014 Q3 | 198.66 Million INR | -20.71% |
| 2014 Q1 | 191.73 Million INR | 42.71% |
| 2014 FY | 750.92 Million INR | 15.64% |
| 2013 Q3 | 168.96 Million INR | -9.95% |
| 2013 Q1 | 158.42 Million INR | 44.67% |
| 2013 Q2 | 187.63 Million INR | 18.44% |
| 2013 Q4 | 134.34 Million INR | -20.49% |
| 2013 FY | 649.38 Million INR | 7.31% |
| 2012 Q4 | 109.51 Million INR | -35.26% |
| 2012 Q3 | 169.16 Million INR | -10.08% |
| 2012 Q2 | 188.13 Million INR | 35.97% |
| 2012 Q1 | 138.36 Million INR | 128.61% |
| 2012 FY | 605.17 Million INR | 3.92% |
| 2011 Q3 | 186.52 Million INR | 0.0% |
| 2011 FY | 582.32 Million INR | 5.99% |
| 2011 Q4 | 60.52 Million INR | -67.55% |
| 2010 FY | 549.4 Million INR | 13.61% |
| 2009 FY | 483.59 Million INR | 400.71% |
| 2008 FY | 96.58 Million INR | 3.09% |
| 2008 Q4 | 9.73 Million INR | 0.0% |
| 2007 FY | 93.68 Million INR | 0.0% |
| 2007 Q4 | 663 Thousand INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Amrutanjan Health Care Limited | 2.09 Billion INR | 9.893% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.54 Million INR | -14940.781% |
| Caplin Point Laboratories Limited | 9.2 Billion INR | 79.505% |
| FDC Limited | 6.58 Billion INR | 71.351% |
| Gufic Biosciences Limited | 4.07 Billion INR | 53.682% |
| Hikal Limited | 5.95 Billion INR | 68.331% |
| Ind-Swift Laboratories Limited | 4.13 Billion INR | 54.349% |
| IOL Chemicals and Pharmaceuticals Limited | 4.71 Billion INR | 60.016% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -204.099% |
| Medico Remedies Limited | 262.14 Million INR | -619.782% |
| Nectar Lifesciences Limited | 4.82 Billion INR | 60.88% |
| Par Drugs and Chemicals Limited | 529.13 Million INR | -256.594% |
| RPG Life Sciences Limited | 2.48 Billion INR | 24.009% |
| Sequent Scientific Limited | 2.97 Billion INR | 36.655% |
| Shilpa Medicare Limited | 3.56 Billion INR | 47.026% |
| Sigachi Industries Limited | 2 Billion INR | 5.764% |
| Themis Medicare Limited | 2.42 Billion INR | 22.031% |
| Unichem Laboratories Limited | 4.86 Billion INR | 61.215% |
| Venus Remedies Limited | 2.18 Billion INR | 13.549% |
| Wanbury Limited | 1.73 Billion INR | -9.027% |
| ZIM Laboratories Limited | 1.26 Billion INR | -48.828% |
| Lupin Limited | 125.09 Billion INR | 98.492% |
| Innova Captab Limited | 3.46 Billion INR | 45.536% |
| Ind-Swift Limited | 2.17 Billion INR | 13.149% |
| Bajaj HealthCare Limited | 1.47 Billion INR | -28.201% |
| Aurobindo Pharma Limited | 109.54 Billion INR | 98.278% |
| Solara Active Pharma Sciences Limited | -1.65 Billion INR | 213.948% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 69.678% |
| Mangalam Drugs & Organics Limited | 691.19 Million INR | -172.987% |
| Morepen Laboratories Limited | 6.16 Billion INR | 69.375% |
| Laurus Labs Limited | 15.44 Billion INR | 87.786% |
| Aarti Drugs Limited | 8.31 Billion INR | 77.311% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 84.824% |
| Alembic Limited | 1 Billion INR | -88.666% |
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 92.954% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 97.279% |
| Vaishali Pharma Limited | 90.32 Million INR | -1989.021% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 67.643% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -189.135% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 90.394% |
| Eris Lifesciences Limited | 10.42 Billion INR | 81.904% |
| Windlas Biotech Limited | 1.33 Billion INR | -40.937% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 99.27% |
| Orchid Pharma Limited | 2.32 Billion INR | 18.68% |
| Albert David Limited | 1.4 Billion INR | -34.002% |
| Hester Biosciences Limited | 1.27 Billion INR | -48.146% |
| Sakar Healthcare Limited | 699.58 Million INR | -169.712% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 54.239% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 67.363% |
| Divi's Laboratories Limited | 32.44 Billion INR | 94.184% |
| Mankind Pharma Limited | 42.19 Billion INR | 95.528% |
| Neuland Laboratories Limited | 8.24 Billion INR | 77.123% |
| J. B. Chemicals & Pharmaceuticals Limited | 15.25 Billion INR | 87.634% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 98.493% |
| Wockhardt Limited | 7.72 Billion INR | 75.559% |
| Bal Pharma Limited | 770.19 Million INR | -144.985% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 98.847% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 48.941% |
| Alkem Laboratories Limited | 52.29 Billion INR | 96.392% |
| Valiant Laboratories Limited | 138.02 Million INR | -1267.007% |
| Ajanta Pharma Limited | 21.06 Billion INR | 91.042% |
| Bafna Pharmaceuticals Limited | 452.15 Million INR | -317.307% |
| Aarey Drugs & Pharmaceuticals Limited | 113.02 Million INR | -1569.364% |
| Granules India Limited | 16.79 Billion INR | 88.768% |
| Medicamen Biotech Limited | 495.49 Million INR | -280.804% |
| Ipca Laboratories Limited | 48.58 Billion INR | 96.116% |
| Brooks Laboratories Limited | 65.62 Million INR | -2775.443% |
| Syncom Formulations (India) Limited | 559.5 Million INR | -237.24% |
| Piramal Enterprises Limited | 8.04 Billion INR | 76.541% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 95.965% |
| NATCO Pharma Limited | 25.73 Billion INR | 92.668% |
| Suven Life Sciences Limited | -200.79 Million INR | 1039.688% |
| Krebs Biochemicals & Industries Limited | -108.74 Million INR | 1835.097% |
| Strides Pharma Science Limited | 14.38 Billion INR | 86.886% |
| Indoco Remedies Limited | 8.04 Billion INR | 76.54% |
| Alpa Laboratories Limited | 188.89 Million INR | -898.897% |
| Lasa Supergenerics Limited | 121.02 Million INR | -1459.007% |
| Sun Pharma Advanced Research Company Limited | 391.06 Million INR | -382.493% |